Supply Chain

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

A panel uncovers how distribution channels are aligning commercialization efforts.

The value of this sometimes-unheralded technology to the pharma industry—as well as potential use cases—are starting to come to light.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.

The transaction reaffirms the CDMO’s interest in growth on a global scale.

The collaboration is centered on standardization and the promotion of safety data sharing when it comes to ground handling.

The 50,000 square-foot plant is expected to augment the compounding and fulfillment experience for telehealth companies.

The 13,400 square-foot Belgium site will expand the company’s branded standardized bioprocessing, cryopreservation, and distribution solution for the cell therapy market, with a focus on leukapheresis starting materials.

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

The conference returns to Lyon, France and promises a timely and relevant agenda that attendees will resonate with.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, forecasts the future of the pharma cold chain regarding technological advancements and changes in market dynamics.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, discusses the significant increase in demand for sustainable practices and outlines the company's initiatives in this area.

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.

In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

The offering will become available in 49 states by next year.

The partnership focuses on the expansion of real-time monitoring and other intelligence services.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses examples of how effective communication can resolve supply chain issues.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses how to handle opposing concerns between supply chain teams and offers communication solutions.

The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses critical conversations that supply chain teams and partners must partake in during API sourcing at LogiPharma USA 2024.

Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses key takeaways from the breakout session at LogiPharma USA 2024.

With the implementation of unit-level traceability, the collaboration is expected to provide additional visibility not only within the aseptic manufacturing process, but the entire supply chain overall.

The hub is intended to assist customers with achieving better sustainability by providing the necessary tools to do so.